Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

被引:257
|
作者
Rugo, Hope S. [1 ]
Delord, Jean-Pierre [2 ]
Im, Seock-Ah [3 ]
Ott, Patrick A. [4 ]
Piha-Paul, Sarina A. [5 ]
Bedard, Philippe L. [6 ]
Sachdev, Jasgit [7 ]
Le Tourneau, Christophe [8 ,9 ,10 ,11 ]
van Brummelen, Emilie M. J. [12 ]
Varga, Andrea [13 ]
Salgado, Roberto [14 ]
Loi, Sherene [14 ]
Saraf, Sanatan [15 ]
Pietrangelo, Dina [15 ]
Karantza, Vassiliki [15 ]
Tan, Antoinette R. [16 ,17 ]
机构
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Inst Claudius Regaud, Dept Med Oncol, Oncolpole Toulouse, France
[3] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med,Canc Res Inst, Seoul, South Korea
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[6] UHN Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada
[7] Scottsdale Healthcare Shea Med Ctr, Breast & GYN Early Trials Program, Scottsdale, AZ USA
[8] Inst Curie, Dept Drug Dev & Innovat, Paris, France
[9] Inst Curie, Dept Drug Dev & Innovat, St Cloud, France
[10] INSERM, Res Unit U900, St Cloud, France
[11] Versailles St Quentin en Yvelines Univ, Montigny Le Bretonneux, France
[12] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands
[13] Gustave Roussy, Drug Dev Dept, Villejuif, France
[14] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[15] Merck & Co Inc, Dept Clin Oncol, Kenilworth, NJ USA
[16] Rutgers Canc Inst New Jersey, Div Med Oncol, Dept Med, New Brunswick, NJ USA
[17] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA
关键词
1ST-LINE THERAPY; OPEN-LABEL; PHASE-2; PALBOCICLIB; IPILIMUMAB; EXPRESSION; MULTICENTER; MONOTHERAPY; LETROZOLE; EFFICACY;
D O I
10.1158/1078-0432.CCR-17-3452
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We investigated the safety and antitumor activity of the anti-programmed death 1 monoclonal antibody pembrolizumab in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2(-)) advanced breast cancer with programmed death ligand 1-positive (PD-L1-positive) tumors in the phase Ib open-label, multicohort KEYNOTE-028 (NCT02054806) study. Patients and Methods: Patients with ER+/HER2(-)advanced breast cancer with PD-L1-positive tumors (combined positive score >= 1) received pembrolizumab (10 mg/kg every 2 weeks) up to 2 years or until confirmed progression/intolerable toxicity. Primary endpoints were safety and overall response rate (ORR), based on Response Evaluation Criteria in Solid Tumors, version 1 (RECIST v1.1) as assessed by investigator review. Results: Between April 2014 and January 2015, 25 patients were enrolled. Median number of prior therapies for breast cancer, including endocrine agents, was 9 (range, 3-15). Median follow-up was 9.7 months (range, 0.7-31.8 months). Three patients experienced partial response (PR) and none experienced complete response (CR), resulting in an ORR of 12.0% (95% CI, 2.5%-31.2%); 16% of patients had stable disease (SD) and clinical benefit rate (CR + PR + [SD for >= 24 weeks]) was 20% (95% CI, 7-41). Median duration of response was 12.0 months (range, 7.4-15.9 months). The incidence of treatment-related adverse events was 64%; nausea (20%) and fatigue (12%) were most common and were predominantly grade 1/2. No treatment-related discontinuations or deaths occurred. Conclusions: Pembrolizumab was well tolerated with modest but durable overall response in certain patients with previously treated, advanced, PD-L1-positive, ER+/HER2(-) breast cancer. (C) 2018 AACR
引用
收藏
页码:2804 / 2811
页数:8
相关论文
共 50 条
  • [31] Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Jhaveri, Komal
    Marme, Frederik
    CANCER TREATMENT REVIEWS, 2024, 123
  • [32] Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer
    Huppert, Laura A.
    Gumusay, Ozge
    Idossa, Dame
    Rugo, Hope S.
    CA-A CANCER JOURNAL FOR CLINICIANS, 2023, 73 (05) : 480 - 515
  • [33] Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer
    Masuda, Norikazu
    Sato, Nobuaki
    Morimoto, Takashi
    Ueno, Takayuki
    Kanbayashi, Chizuko
    Kaneko, Koji
    Yasojima, Hiroyuki
    Saji, Shigehira
    Sasano, Hironobu
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER RESEARCH, 2018, 78 (04)
  • [34] The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
    Rizki, Hirah
    Hillyar, Christopher
    Abbassi, Omar
    Miles-Dua, Sascha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (03)
  • [35] Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial
    Migliaccio, Ilenia
    Romagnoli, Dario
    Galardi, Francesca
    De Luca, Francesca
    Biagioni, Chiara
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Minisini, Alessandro Marco
    Moretti, Erica
    Risi, Emanuela
    Guarducci, Cristina
    Nardone, Agostina
    Biganzoli, Laura
    Benelli, Matteo
    Malorni, Luca
    JCO PRECISION ONCOLOGY, 2024, 8
  • [36] Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer
    Nahleh, ZA
    Jazieh, AR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 631 - 633
  • [37] Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Kim, Jee Hyun
    Im, Seock-Ah
    Sim, Sung Hoon
    Bananis, Eustratios
    Huang, Xin
    Kim, Hyun Seon
    Kim, Sung-Bae
    JOURNAL OF BREAST CANCER, 2021, 24 (01) : 97 - 105
  • [38] Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer
    Gogineni, Keerthi
    Kalinsky, Kevin
    JCO ONCOLOGY PRACTICE, 2022, 18 (04) : 247 - +
  • [39] Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study
    Jiang, Zefei
    Hu, Xichun
    Zhang, Qingyuan
    Sun, Tao
    Yin, Yongmei
    Li, Huiping
    Yan, Min
    Tong, Zhongsheng
    Oppermann, Christina Pimentel
    Liu, Yunpeng
    Costa, Romulo
    Li, Man
    Chen, Xi
    Cheng, Ying
    Ouyang, Quchang
    Liao, Ning
    Wang, Xiaojia
    Wu, Xinhong
    Feng, Jifeng
    Hegg, Roberto
    Setty, Govindbabu Kanaka
    Agarwal, Amit
    Bajpai, Jyoti
    Cheng, Jing
    Girotto, Gustavo
    Goswami, Chanchal
    Hu, Wenjing
    Huang, Jian
    Portugal, M. A. Coccia
    Yang, Jin
    Zheng, Rongsheng
    Franke, Fabio Andre
    Liu, Qiang
    Liu, Yunjiang
    Lu, Yongkui
    Souza, Cristiano
    Yu, Shiying
    Kilara, Nalini
    Panchal, Harsha
    Singh, Ashish
    Nag, Shona
    Liu, Jian
    Rapoport, Bernardo
    Tabane, Neonyana Keorapetse Rebecca
    Wang, Hongxia
    Wang, Ning
    Han, Rubing
    Zhang, Wanli
    CANCER RESEARCH, 2021, 81 (04)
  • [40] MONITORING AND MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH RIBOCICLIB COMBINATION THERAPY IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Britto, Michele
    ONCOLOGY NURSING FORUM, 2018, 45 (02)